Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Modified VR-CAP and Acalabrutinib as First Line Therapy for Transplant-Eligible Patients With Mantle Cell Lymphoma

NCT04626791 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT04626791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04626791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Modified VR-CAP and Acalabrutinib as First Line Therapy for Transplant-Eligible Patients With Mantle Cell Lymphoma
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 3, 2021
Completion date
August 3, 2028
Enrollment
41 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma